Minimum Residual Disease in Acute Lymphoblastic Leukemia
In this segment, Jeffrey Lancet, MD; Raoul Tibes, MD; and Mark R. Litzow, MD, describe various methodologies in monitoring minimum residual disease in acute ...
OncLiveTV
MRD Monitoring in Acute Lymphoblastic Leukemia
In this segment, Raoul Tibes, MD, PhD, discusses risk stratification based on minimal residual disease monitoring in patients with acute lymphoblastic leukemia ...
OncLiveTV
MRD in AML: What is it and what do I do about it?
Earn CME: https://naccme.com/program/7311 In this presentation from the 'FLT3 Targets in RIn this presentation from the 'R AML: Evaluating Emerging Clinical ...
ImedexCME
What is MRD, or Minimal Residual Disease?
In this week's video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used for ongoing monitoring. BOTTOM ...
International Myeloma Foundation
Treatment of minimal residual disease in AML patients
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY discusses minimal residual disease (MRD) found in acute myeloid leukemia ...
VJHemOnc – Video Journal of Hematological Oncology
Prof. Maurice O'Gorman - B Acute Lymphoblastic Leukaemia Minimal Residual Disease Testing
Prof. Maurice O'Gorman - B Acute Lymphoblastic Leukaemia Minimal Residual Disease Testing by Flow Cytometry: Approval, Validation and Challenges in the ...
UKNEQASLI
ALL: Therapy for Post-Induction MRD-Positivity
Mark R. Litzow, MD; Ryan D. Cassaday, MD; Aaron C. Logan, MD, PhD; and Bijal D. Shah, MD, discuss secondary treatment options for a patient with acute ...
OncLiveTV
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses his talk on the utility of measurable residual disease (MRD) ...
VJHemOnc – Video Journal of Hematological Oncology
The importance of minimal residual disease in ALL
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines his talk on minimal residual disease (MRD) and how ...
VJHemOnc – Video Journal of Hematological Oncology
What is Minimal Residual Disease? (AML)
Dr. Sahra Ali, a consultant haematologist at Hull and East Yorkshire Hospital Trust, talks to Leukaemia Care from EHA about what MRD is.
Leukaemia Care
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Felicitas Thol, MD, from Hannover Medical School, Hannover, Germany, discusses whether IDH1 and IDH2 mutations are good markers for minimal residual ...
VJHemOnc – Video Journal of Hematological Oncology
Minimal Residual Disease in Chronic Lymphocytic Leukemia
In this segment, Jennifer Brown, MD, PhD; Javier Pinilla-Ibarz, MD, PhD; and William Wierda, MD, PhD, assess the value minimal residual disease in the ...
OncLiveTV
Dr. Farhad Ravandi on How to Treat Minimal Residual Disease
Farhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center, discusses minimal residual disease (MRD). Ravandi says ...
Targeted Oncology
How is minimal residual disease managed in patients with ALL?
Prof Renato Bassan speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about minimal residual disease (MRD) in acute lymphoblatic leukaemia ...
ecancer
MRD testing in acute leukemias
Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual disease ...
VJHemOnc – Video Journal of Hematological Oncology
Minimal residual disease (MRD) in CLL: Is it clinically relevant?
In this presentation from the Lymphoma & Myeloma 2017, Dr. Peter Hillmen discusses the clinical relevance of minimal residual disease (MRD). Earn CME ...
ImedexCME
Flow cytometry vs. molecular methods for MRD testing in acute leukemias
Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Robin Foà, MD, from ...
VJHemOnc – Video Journal of Hematological Oncology
Challenges with measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele, MD, PhD of VU University Medical Center, Amsterdam, Netherlands discusses the challenges of measurable residual disease (MRD) ...
VJHemOnc – Video Journal of Hematological Oncology
Importance of MRD Testing in Acute Lymphoblastic Leukemia
Mark R. Litzow, MD; Aaron C. Logan, MD, PhD; and Bijal D. Shah, MD, provide a background on the current state of MRD testing in acute lymphoblastic ...
OncLiveTV
Dr. Radich on Impact of MRD in Acute Vs Chronic Leukemias
Website: https://www.onclive.com Twitter: https://twitter.com/OncLive Facebook: https://www.facebook.com/OncLive/ LinkedIn: ...
OncLiveTV
Minimal residual disease: a key determinant of ALL treatment response
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker in predicting patient ...
VJHemOnc – Video Journal of Hematological Oncology
Measurable Residual Disease in Acute Myeloid Leukemia MRD in AML
Prof. Christopher S. Hourigan DM DPhil FACP FRCP Chief, Laboratory of Myeloid Malignancies National Heart, Lung and Blood Institute National Institutes of ...
International Academy for Clinical Hematology IACH
AML: Induction Therapy and Minimal Residual Disease
Richard M. Stone, MD, and Hervé Dombret, MD, provide insight on factors to consider in the initial approach to acute myeloid leukemia and the goals of ...
OncLiveTV
Acute leukemias: is MRD already a surrogate for survival?
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the potential of MRD status as a prognostic ...
VJHemOnc – Video Journal of Hematological Oncology
Acute Lymphoblastic Leukemia: Challenges in MRD Testing
Mark R. Litzow, MD; Aaron C. Logan, MD, PhD; Bijal D. Shah, MD; and Ryan D. Cassaday, MD, reflect on challenges presented by minimal residual disease ...
OncLiveTV
Dr. Litzow on Assessing Minimal Residual Disease in Patients With ALL
Mark R. Litzow, MD, chair, ECOG-ACRIN Leukemia Committee, professor of medicine, Division of Hematology, Mayo Clinic, discusses ways of conducting ...
Targeted Oncology
Measurable residual disease in AML
Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, discusses the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). Prof.
VJHemOnc – Video Journal of Hematological Oncology
AML On The Go - Minimal Residual Disease Eradication with Epigenetic
Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia - pub. 10/24/17 AMLOTG15 Brittany Knick ...
Oncology.TV
ALL: Combining paediatric-type therapy with minimal residual disease
Dr Rambaldi speaks with ecancertv at ASH 2016 about the final results of the Northern Italy Leukaemia Group (NILG) trial combining paediatric-type therapy with ...
ecancer
Strategies to Assess Minimal Residual Disease
A panel of experts elucidate the methods used to measure minimal residual disease in acute lymphoblastic leukemia. Website: https://www.onclive.com Twitter: ...
OncLiveTV
How has MRD changed our ability to diagnose leukemia?
Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video, Elizabeth Macintyre, MD, PhD, ...
VJHemOnc – Video Journal of Hematological Oncology
An Overview of Minimal Residual Disease Testing
Michael L. Wang, MD, provides an overview of minimal residual disease's value in treating lymphoid malignancies.
OncLiveTV
Immunophenotyping of Acute Leukemia - Part 4 of 4
Use of FCM in the diagnosis of Ambiguous Leukemias Use of FCM in the detection of Minimal Residual Disease.
tamer273
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 4
Duke Margolis
Identifying patients at different risk of relapse in childhood acute lymphoblastic leukemia (ALL)
Martin Schrappe, MD, FRCP, from the University Medical Center Schleswig-Holstein, Kiel, Germany, discusses the AIEOP-BFM ALL 2000 (NCT01117441) trial, ...
VJHemOnc – Video Journal of Hematological Oncology
Acute Lymphoblastic Leukemia: Optimizing MRD Testing
Mark R. Litzow, MD; Anthony S. Stein, MD; Aaron C. Logan, MD, PhD; and Bijal D. Shah, MD, reflect on the optimal time to test for minimal residual disease and ...
OncLiveTV
Debate: Should Consolidation and Minimal Residual Disease Testing be Used? - Yes
Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a series that focuses on ...
ImedexCME
The evolution of MRD-guided therapy for leukemia
Richard Dillon, MBBS, from King's College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML).
VJHemOnc – Video Journal of Hematological Oncology
Module 2 Blinatumomab for minimal residual disease in adults with B cell precursor acute lymphobla
Visit https://www.annenberg.net/Lymphoblastic-Leukemia-CME for the entire activity. In this CME activity Elias Jabbour, MD, reviews some of the recent clinical ...
Annenberg Center for Health Sciences
ASH Impact Series: Wendy Stock, MD - How I Treat ALL in First Complete Remission
Wendy Stock, MD, discusses the current tools to measure minimal residual disease in acute lymphoblastic leukemia (ALL), how minimal residual disease ...
American Society of Hematology
MRD Monitoring in Acute Myeloid Leukemia
Minimal residual disease (MRD) after therapy has unequivocal prognostic value in acute myeloid leukemia. There is growing evidence that the presence of MRD ...
UW Video
MRD to determine risk of relapse after induction in AML
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the use of measurable residual disease ...
VJHemOnc – Video Journal of Hematological Oncology
